Antimicrobials
Daptomycin

Daptomycin

Restricted

Low
N/A
$$ ($26-$100/day)

Spectrum of Activity

General Information

CPK at least once weekly

  • Myopathy, muscle weakness

  • Rhabdomyolysis

HMG-CoA Reductase Inhibitors (Statins)

  • May enhance the adverse/toxic effect of DAPTOmycin
  • Specifically, the risk of skeletal muscle toxicity may be increased
  • Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin
  • If used together, regular (i.e. at least weekly) monitoring of CPK concentrations is recommended

Cubicin, Cubicin-RF

Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection

  • Distribution: 0.1 L/kg
  • Protein Binding: 90% to 93%
  • Metabolism: Minor
  • Half-Life Elimination: 8-9 hrs
  • Excretion
    • Urine (78%; primarily as unchanged drug)
    • Feces (5.7%)
  • Clearance: 8.3-9 mL/hr/kg